Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion
Authors: Gil Jeovanis , Kim Yonghyo , Szeitz Beáta , Doma Viktória , Çakır Uğur , de Almeida Natália Pinto , Hagemeijer Yanick Paco , Guryev Victor , Johansson Jenny G , Sharma Yogita , Parada Indira Pla , Horvath Zsolt , de Siqueira Guedes Jéssica , Monnerat Gustavo , Carneiro Gabriel Reis Alves , CS Nogueira Fábio , Lee Boram , Oskolas Henriett , Kuroli Enikő , Hársing Judit , Sugihara Yutaka , Kuras Magdalena , Appelqvist Roger , Wieslander Elisabet , Domont Gilberto B , Baldetorp Bo , Hong Runyu , Huszty Gergely , Vizkeleti Laura , Tímár József , Fenyö David , Betancourt Lazaro Hiram , Jakobsson Johan , Malm Johan , Sanchez Aniel , Szász A. Marcell , Horvatovich Peter , Rezeli Melinda , Kárpáti Sarolta , Marko-Varga György 
Published: April 2021

Malignant melanoma (MM) develops from the melanocytes and in its advanced stage is the most aggressive type of skin cancer. Here we report a comprehensive analysis on a prospective cohort study, including non-tumor, primary and metastasis tissues (n=77) with the corresponding plasma samples (n=56) from patients with malignant melanoma. The tumors and surrounding tissues were characterized with a combination of high-throughput analyses including quantitative proteomics, phosphoproteomics, acetylomics, and whole exome sequencing (WES) combined with in-depth histopathology analysis. Melanoma cell proliferation highly correlates with dysregulation at the proteome, at the posttranslational- and at the transcriptome level. Some of the changes were also verified in the plasma proteome. The metabolic reprogramming in melanoma includes upregulation of the glycolysis and the oxidative phosphorylation, and an increase in glutamine consumption, while downregulated proteins involved in the degradation of amino acids, fatty acids, and the extracellular matrix (ECM) receptor interaction. The pathways most dysregulated in MM including the MAP kinases-, the PI3K-AKT signaling, and the calcium homeostasis, are among the most affected by mutations, thus, dysregulation in these pathways can be manifested as drivers in melanoma development and progression.

The phosphoproteome analysis combined with target-based prediction mapped 75% of the human kinome. Melanoma cell proliferation was driven by two key factors: i) metabolic reprogramming leading to upregulation of the glycolysis and oxidative phosphorylation, supported by HIF-1 signaling pathway and mitochondrial translation; and ii) a dysregulation of the immune system response, which was mirrored by immune system processes in the plasma proteome. Regulation of the melanoma acetylome and expression of deacetylase enzymes discriminated between groups based on tissue origin and proliferation, indicating a way to guide the successful use of HDAC inhibitors in melanoma. The disease progression toward metastasis is driven by the downregulation of the immune system response, including MHC class I and II, which allows tumors to evade immune surveillance. Altogether, new evidence is provided at different molecular levels to allow improved understanding of the melanoma progression, ultimately contributing to better treatment strategies.

TOC figure